Alembic PharmaQ2 FY26

Alembic Pharma Q2 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,050.65P/E: 23.0Market Cap: ₹20.7K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 1

Fundraise

N/A

Order

N/A

Capex

Yes

2 of 3 growth signals are positive.

Full analysis

Revenue guidance

Category 3
Future growth expectations for Alembic Pharmaceuticals as per the transcript include: - Continued ramp-up of new launches expected to improve sales volumes, especially in the US and Rest of World (ROW) markets. - India business aims to catch up with and potentially outperform market growth soon, with improvements expected from productivity enhancements and stabilized brands like Azithral. - US business growth expected to be sustained by new product launches such as Entresto and Pivya (launch planned in late Q4 FY26), focusing on branded segments. - ROW generics projected to grow at 15-20% annually. - EBITDA margins targeted to improve towards 18-20% over the next couple of years with higher capacity utilization and better operational leverage. - Growth in API business expected at about 10%. - Investments in specialty injectables and peptides to start yielding approvals and revenue in coming quarters. - Animal health, Gynecology, and Ophthalmology segments to continue accelerated performance in India.

See what Alembic Pharma management said on margin guidance — free account, 30 seconds.

Fundraise plans

  • There is no specific mention of any current or future fundraising plans through debt or equity in the provided transcript.
  • Net debt increased from INR 967 crores in June 2025 to INR 1,280 crores as of September 30, 2025, primarily due to borrowing to fund working capital and the acquisition of Utility Therapeutics.
  • The management indicated that net debt levels, excluding the Pivya launch, are expected to gradually reduce in FY 2027 with new product launches and growth from new facilities.
  • There was no explicit discussion or guidance about raising additional debt or equity financing during the call.

See what Alembic Pharma management said on order book — free account, 30 seconds.

Capex plans

Yes
  • Alembic Pharmaceuticals has commercialized new injectable and oncology plants over the last two and a half years, currently running below anticipated utilization but with expected ramp-up in H2 FY26 and FY27 due to upcoming product approvals and launches.
  • No specific new capex figures disclosed yet; unabsorbed overheads exist due to investments in new facilities.
  • Investment focus remains on complex and high-value areas such as injectables, peptides (e.g., Mounjaro Tirzepatide), oral solids, and drug discovery with emphasis on early entry opportunities.
  • Recent acquisition of Utility Therapeutics to enter the US branded market with Pivya; involves upfront and milestone payments and profit-sharing, indicating strategic investment in specialty branded segment.
  • Gradual ramp-up of the US branded business with investment in building a small field force starting end Q4 FY26, implying ongoing marketing and operational investments.
  • Management expects margin improvement with better capacity utilization and growth from new facilities in coming years, targeting EBITDA margin of 18-20% in the next couple of years.

Track Alembic Pharma — get its next earnings analysis in your feed

How does Alembic Pharma rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature
ThisAlembic Pharma
Rev 3Mar 1

How does Alembic Pharma rank in Pharmaceuticals & Biotechnology?

Compare Alembic Pharma against every Pharmaceuticals & Biotechnology company (Q2 FY26) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Others in Pharmaceuticals & Biotechnology this season

  • Lasa Supergeneri (Q2 FY27)

    306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra

  • Themis Medicare (Q2 FY27)

    Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q

  • Panacea Biotec (Q2 FY27)

    September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Biofil Chemicals (Q2 FY27)

    Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →